SHR-1139 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Trial of SHR-1139 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Jiangsu Hengrui Pharmaceuticals…announced that China’s National Medical Products Administration (NMPA) has granted approval for clinical trials of two independently developed biologics: SHR‑3045 injection for rheumatoid arthritis (RA) and SHR‑1139 injection for ulcerative colitis (UC) (flcube.com)

New trial • Rheumatoid Arthritis • Ulcerative Colitis

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=145 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis

A Trial of SHR-1139 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Atridia Pty Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis

A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Dermatology • Immunology • Psoriasis